High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease-Reference-Cited by-同舟云学术

High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease

Published:2018-03-31 Issue:8 Volume:38 Page:1395-1401
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Sanai Faisal M.¹^ORCID,Alghamdi Abdullah S.²,Afghani Ahmad A.³,Alswat Khalid⁴,AlZanbagi Adnan⁵,Alghamdi Mosfer N.⁶,AlMousa Abdallah⁷,Aseeri Mohammed⁸,Assiri Abdullah M.⁹,Babatin Mohamed A.²

Affiliation:

1. Gastroenterology Unit; Department of Medicine; King Abdulaziz Medical City; Jeddah Saudi Arabia

2. Gastroenterology Unit; Department of Medicine; King Fahad Hospital; Jeddah Saudi Arabia

3. Gastroenterology Unit; Department of Medicine; King Fahad Hospital; Madinah Almunawarrah Saudi Arabia

4. Gastroenterology Unit; Department of Medicine & Liver Disease Research Center; College of Medicine; King Saud University; Riyadh Saudi Arabia

5. Gastroenterology Unit; Department of Medicine; King Abdallah Medical City; Makkah Saudi Arabia

6. Gastroenterology Unit; Department of Medicine; AlHada Armed Forces Hospital; Taif Saudi Arabia

7. Hepatology Department; King Fahad Specialist Hospital; Buraidah Saudi Arabia

8. Pharmacy Department; King Abdulaziz Medical City; Jeddah Saudi Arabia

9. Infectious Disease Department; King Fahd Medical City; Riyadh Saudi Arabia

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13674/fullpdf

Reference18 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd Hanafiah;Hepatology,2013

2. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Polaris Observatory HCV Collaborators;Lancet Gastroenterol Hepatol,2017

3. SASLT guidelines: update in treatment of hepatitis C virus infection;Alghamdi;Saudi J Gastroenterol,2016

4. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members;Niu;Am J Kidney Dis,1993

5. The prevalence of hepatitis C virus antibodies among hemodialysis patients;Zeldis;Ann Intern Med,1990

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond genotype‐4: Direct‐acting antiviral agents in patients with chronic hepatitis C infection from the Eastern Province of Saudi Arabia;Health Science Reports;2024-01

2. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis;Frontiers in Public Health;2023-09-29

3. Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease;Arab Journal of Gastroenterology;2023-02

4. A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD;Kidney International Reports;2023-02

5. Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure;Clinical and Experimental Hepatology;2023